<DOC>
	<DOCNO>NCT00179608</DOCNO>
	<brief_summary>This study determine MDT intravenous DTIC administer combination fix dose oral lenalidomide subject metastatic malignant melanoma previously untreated systemic chemotherapy . This study evaluate safety preliminary efficacy combination lenalidomide DTIC . Subjects receive lenalidomide 14 consecutive day DTIC day one 21 day cycle .</brief_summary>
	<brief_title>Study Combination Lenalidomide DTIC ( Dacarbazine ) Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent document 2 . Age great equal 18 year time signing Informed Consent 3 . Be able adhere study visit schedule protocol requirement 4 . Histological documentation malignant melanoma evidence metastatic disease 5 . For 10 patient enrolled MTD , least one measurable lesion must present ( see Appendix II ) 6 . ECOG performance status 0 , 1 2 ( see Appendix I ) 7 . Laboratory test within range : 1 . Absolute neutrophil count great equal 1,500/uL 2 . Platelet count great equal 100,000/uL 3 . Serum creatinine less equal 1.5 mg/dL 4 . Total bilirubin less equal 1.5 mg.dL 5 . AST ( SGOT ) / ALT ( SGPT ) less equal 2 time upper limit normal ( ULN ) 8 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use least two method adequate contraceptive ( oral , injectable , implantable hormonal contraceptive , tubal ligation , intrauterine device , barrier contraceptive spermicide , contraceptive skin patch vasectomize partner ) study drug 9 . All acute adverse effect ( exclude alopecia prior therapy must resolve less equal grade 1 ( NCI CTCAE v3.0 ) 10 . Patients must able take medication orally 1 . Pregnant lactating female 2 . Any serious medical condition , include psychiatric illness prevent patient signing inform consent place patient unacceptable risk he/she participate study . 3 . Prior treatment systemic chemotherapy . Patients receive prior immunotherapy , include thalidomide , radiotherapy remain eligible . Lesions within prior field radiation may use indicator lesion evidence disease progression site . 4 . Prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless patient free disease least 3 year . 5 . Use thalidomide biologic response modifier therapy within 14 day Day 1 , Cycle 1 6 . Prior great equal grade 2 allergic reaction thalidomide 7 . Prior desquamate rash take thalidomide 8 . Any prior use lenalidomide 9 . Concurrent use anticancer agent 10 . Radiation surgical treatment melanoma within 28 day start study treatment 11 . Active infection 12 . Central nervous system ( CNS ) metastases 13 . Patients &gt; grade2 neuropathy 14 . Patients know HIV positivity AIDSrelated illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CC-5013</keyword>
	<keyword>CC5013</keyword>
	<keyword>celgene</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Metastatic Malignant Melanoma</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>